Health Technology Assessment (HTA)

Health Technology Assessment (HTA) is a multidisciplinary process that uses explicit methods to determine a health technology’s value for healthcare decision-making. Attitudes towards HTA vary globally, with some countries using a variety of methods and analyses and others hardly any.

Woman runner at the start line taking position on a running trac
Publication

Achieving Accelerated Patient Access to Cancer Care in Europe 

3 November 2025

In recent years, the European Medicines Agency (EMA) has introduced several accelerated pathways (APs) to enable earlier access to promising therapies where there is high unmet medical need, particularly in oncology.

Insights

Around the World in HTAs: Saudi Arabia – Navigating the healthcare and HTA landscape

24 September 2025

The next stop in our around the world in HTAs adventure is Saudi Arabia. This blog breaks down how the Kingdom is reshaping access to new health technologies through regulatory reform, a formal HTA framework, and value-based care. It provides a comprehensive overview of the structural and regulatory reforms underway as part of Vision 2030, highlighting how these changes are reshaping the way new health technologies are evaluated, priced, and brought to market.

Insights

Around the world in HTAs: China – From fragmentation to function

2 September 2025

In this Insights series, Around the World in HTAs, we shed light on HTA around the world. In this edition Yawen Jiang, Meng Li and Claud Theakston take us to China.

Insights

Reflections from the Region: Healthcare transformation in the Middle East

18 June 2025

It’s not often that you witness a health system reinvent itself in real-time. And yet, this is precisely what is happening across the Middle East.

Insights

How Widely Are QALYs Used in OECD Countries? A Snapshot of International Practices

11 June 2025

As healthcare systems strive to allocate resources efficiently, the use of economic evaluation metrics like Quality-Adjusted Life Years (QALYs) has become increasingly important.

Insights

Around the world in HTAs: Argentina – Long Road to Institutionalizing HTA

9 June 2025

In this Insights series, Around the World in HTAs, we shed light on HTA around the world. In this edition, Andrés Pichon-Riviere, Federico Augustovski, and Martina Garau take us to Argentina.

A balloon floating about the savannah
Insights

Around the World in HTAs: Kenya – Riding the Waves of Change

19 May 2025

In this Insights series, Around the World in HTAs, we shed light on HTA around the world. In this edition, Angela Kairu and Edwine Barasa of the KEMRI Wellcome Trust Research Programme, and Paul Oyalo of OHE, take us to Kenya.

Publication

Understanding the Full Value of Long-Acting Therapies: less is more?

7 May 2025

Long-acting (LA) therapies represent a significant innovation in pharmaceutical development by offering a sustained drug effect with reduced administration frequency.

Publication

An Analysis of NICE’s Optimised Decisions from 2015 to 2024

1 May 2025

The National Institute for Health and Care Excellence (NICE) is the body responsible for recommending medicines for use within the National Health Service (NHS) in England.